The Federal Circuit recently affirmed the U.S. government's extensive licensing rights under the Bayh-Dole Act in a dispute involving an Alzheimer's disease research patent. This case underscores the act's reach, including work predating funding agreements, in the context of transgenic mice used for Alzheimer’s research.
